2025

iOnctura commences randomized Phase II study in metastatic uveal melanoma

GENEVA and AMSTERDAM, March 20, 2025 /PRNewswire/ — iOnctura, a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers, today announces it has dosed the first patient in the randomized Phase II OCULE-01 study investigating lead asset roginolisib in patients with metastatic uveal melanoma (UM), a rare cancer of the eye.

Read More

The Promise of OBX-115, a Novel TIL Therapy, in Melanoma

Cancer treatment vaccines have been in development since 2010, when the first was approved for prostate cancer, followed by another in 2015 for melanoma. While many therapeutic (rather than preventive) cancer vaccines have been researched since then, none have received approval. A major challenge in their development is identifying tumor antigens that are distinct enough from normal cells to trigger a strong immune response.

Read More
MRV News
Melanoma News
Archive
Menu